Open AccessCCN1: a novel target for pancreatic cancer
Author(s) -
Leask Andrew
Publication year - 2011
Publication title -
journal of cell communication and signaling
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 44
eISSN - 1873-961X
pISSN - 1873-9601
DOI - 10.1007/s12079-011-0127-1
Subject(s) - cyr61 , pancreatic cancer , matricellular protein , cancer , intervention (counseling) , medicine , bioinformatics , carcinogenesis , drug discovery , drug , cancer research , computational biology , biology , ctgf , pharmacology , microbiology and biotechnology , receptor , growth factor , psychiatry , extracellular matrix
Members of CCN family of matricellular proteins are being increasingly recognized by the translational research community as representing excellent targets for drug intervention. Although much effort has been expended in outlining the mechanisms involved in pancreatic carcinogenesis, the precise molecular pathways involved remain incompletely understood, and appropriate targets for drug intervention remain elusive. A recent exciting report by Haque and colleagues (Mol Cancer. 2011 Jan 13;10:8) provides strong evidence that CCN1 (cyr61) is a potential therapeutic target in pancreatic cancer.